Lea’s Shield Clinical Investigator Warned For Improper Informed Consent
This article was originally published in The Gray Sheet
Executive Summary
Informed consent and records violations by clinical investigator Mitchell Creinin, MD, University of Pittsburgh, during the pivotal trial for Yama, Inc.'s Lea's Shield were significant enough to draw a warning letter, but did not hinder approval of the PMA
You may also be interested in...
Yama Lea’s Shield Contraceptive Market Strategy To Focus On Convenience
Yama, Inc. is positioning its Lea's Shield reusable barrier contraceptive device as "more convenient" than traditional diaphragms
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.